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ASPERGILLOSIS is the second most imponant cause 
of fungal. infection after liver transplantaUon (LTx). 
with a mortality approaching 100%. In a previous study, 
we observed a 4% frequency of invasive aspergillosis in 
101 consecutive LTx recipients. I Outcome depends on 
early treatment. however. the diagnosis of this disease is 
very difficult.2 
The introduction of FK 506. allowed us to evaluate the 
impact of this new immunosuppressive agent on the inci-
dence and outcome of aspergillosis following L Tx. and to 
compare this to a group of patients under traditional 
cyclosporine (Cy A) therapy. 
METHODS 
Patient Selection 
Pathology and microbiology records were reviewed during the 
period from 1981 to 1990. and 32 cases of invasive aspergillosis 
occurring after liver transplantation were identified. Their inpa-
tient and outpatient charts were reviewed. 
Definitions 
a~finiDiv~ diagnosIS: Histologic evidence of tissue invasion at 
biopsy or autopsy (24 of 32. 75%). 
mrobabl~ diagnosIS: Characteristic clinical picture combined 
with laclt of response to antibacterial agents and presence of 
repeated positive cultures for Aspergillus species (8 of 32.25%). 
aisD~m;naI~d aAp~rglllosiA: Histologic proven invasion in au-
topsy of two or more noncontiguous organs (16 of 32. 50%). 
Immunosuppression 
Two protocols were used: (a) CyA and steroids. and (b) FK 506 
with low-dose steroids (20 mg/d). 
Rejection episodes were treated with a I-g dose or S-da y recycle 
of methylprednisolone. OKT3 monoclonal antibody was used for 
treatment of steroid-resistant rejection. 
AntIbIotic: ProphytaxiS 
Perioperauve IV cefotaxime and aml'icillin 4 g/d were adminis· 
tered to all l'8tients. Funp! prophylaxis included oral nystatin 2 
millions uniu daily. 
Risk Factors 
We analyzed four prettansl'lant (hel'8tocellular disease. ALT 
>60 and steroid usel and seven posltransplant vanables (I V 
antibiotics >5 days. cumulative SUrgical time> 12 hours. re.trans. 
plantation. additional abdominal operations. choledochoJeJunos-
tomy. OKT3. and additional steroids I. 
Statistics 
Prol'Orttons were analyzed with chi-square test or Fisher's Exact 
Test when data were scarce. 
RESULTS 
The characteristics of the popUlation are shown in Table I. 
During the 100year study period. 2180 patients underwent 
OLT at our institution. and 32 patients developed invasive 
aspergillosis for an overall rate of 1.5%. 
Cy A and steroid immunosuppression were used in 1247 
patients. and 30 patients were identified with invasive 
aspergillosis. for an incidence of 2.4%, and a monality of 
94% (29 of 30). Two cases of aspergillosis occurred from 
among 933 patients receiving FK 506 and low-dose ste-
roids for an incidence of 0.2% (P < .01). and a monality of 
50% (\ of 21. 
The mean time to diagnosis after OLT was 101 :!: 160 
days in the Cy A group and 31 :!: 13 days in the FK 506 
group. The median time of dia.gnosis was 35 days in the 
Cy A group and 31 days in FK 506 group. One FK 506 
patient died of disseminated aspergillosis on day 219. 
which was significantly longer than the mean survival time 
of 119 days seen in CyA patients. The other patient is free 
of disease after completing 6 months of treatment that 
included amphotericin Band itraconazole. 
The presenting symptoms in FK 506 patients included 
fever and respiratory complaints in both. and skin involve-
ment in one. Fever. respiratory. and neurological manifes-
tations were the most frequent presenting symptoms in the 
CyA group. In both FK 506 and CyA patients. concomi-
tant bacterial. fungal, and viral infections were frequent. 
When four pretransplant risk factors were analysed .... 
higher occurrence of hepatocellular disease in FK 506 
patients was found. No pallent receIving FK S06 reqUIred 
Table 1. ComparilOn at Aspergilioais on FK 508 and CyA 
Total CyA FK506 
Total OlT 2180 1247 93 
AspergIllus 32 (1.5%) 30 (2.4%)" 2 (0.2"10)· 
Time diagnostS 97:t 162 101 :t 166 31 :t 13 
(mean=: SO) 
Time diagnostS 34.5 35 31 
(median) 
Died 30(94%) 29(97%) 1 (50%1 
'p< .01. 
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ASPERGILLOSIS IN LTx PATIENTS 
OKTI or retransplantation. whereas in the eyA group, 
73% of patients were treated with OKTI and 70% needed 
retransplantation. These findings were the most significant 
of the seven posttransplant variables analysed. 
DISCUSSION 
Aspergillosis continues to be associated with very high 
mortality after liver transplantation. In this series. only 
two patients survived. and in only 56% of patients was the 
diagnosis made before death. Variables found to be corre-
lated with higher rates of fungal infection in our previous 
repons 1.3 are also associated with aspergillosis in this 
series. The typical patient at risk for aspergillosis is rela-
tively young, has undergone a long cumulative surgical 
time. and demonstrates persistent fever despite antimicro-
bial therapy in the first months after transplantation. 
With the introduction the new immunosuppressive 
agent. FK 506. we observed a decrease in the incidence of 
3041 
aspergillosis. This phenomenon occurred in spite of the 
potent immunosuppressive properties of FK. 506. suggest-
ing that this new drug has the ability to decrease other 
factors for infection. such as lowering steroid usage with-
out increasing the risk of rejection and the subsequent 
need for augmented immunosuppression and/or retrans-
plantation. 
Improvement in patient management after LTx has 
allowed us to increase patient and graft survival to levels 
unparalleled only a few years ago. The introduction of 
novel agents such as fK 506 will contribute to a funher 
improvement in overall morbidity. 
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